2012 Fiscal Year Final Research Report
Innovation of a novel anti-hypertensive therapy due to the inhibitionof aldosterone synthase (CYP11B2) gene expression
| Project/Area Number |
22591006
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Endocrinology
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
SUGAWARA Akira 東北大学, 大学院・医学系研究科, 教授 (90270834)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KUDO Masataka 東北大学, 病院, 講師 (20509583)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NOGUCHI Naoya 仙台市立病院, 耳鼻咽喉科, 医長 (20333792)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Keywords | 内分泌学 / 分子高血圧学 |
|---|
| Research Abstract |
In the present study, we elucidated that both PPARγ and RXR agonists suppressed aldosterone synthase (CYP11B2) expression at the gene transcription level, while the supernatant of adipocytes induced CYP11B2 transcription activation. Additionally, we generated a stable H295R cell line expressing CYP11B2 promoter/luciferase chimeric reporter construct. Based on these observations, we are going to develop novel anti-hypertensive drugs.
|
Research Products
(28 results)
-
-
-
[Journal Article] All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-{delta}2011
Author(s)
Uruno A, Noguchi N, Matsuda K, Nata K, Yoshikawa T, Chikamatsu Y, Kagechika H, Harigae H, Ito S, Okamoto H, Sugawara A.
-
Journal Title
J Leukoc Biol
Volume: 90
Pages: 235-247
DOI
Peer Reviewed
-
[Journal Article] Peroxisome proliferator-activated receptor-γ suppresses CYP11B2 expression and aldosterone production2011
Author(s)
Uruno A, Matsuda K, Noguchi N, Yoshikawa T, Kudo M, Satoh F, Rainey WE, Hui XG, Akahira JI, Nakamura Y, Sasano H, Okamoto H, Ito S,Sugawara A
-
Journal Title
J Mol Endocrinol
Volume: 46
Pages: 37-49
DOI
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
